BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates - BiomX (AMEX:PHGE)

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates - BiomX (AMEX:PHGE)

Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success  BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a confe…